about
Deregulated signaling pathways in glioblastoma multiforme: molecular mechanisms and therapeutic targetsCirculating tumor cells in the diagnosis and management of pancreatic cancerBeneficial effects of secretory leukocyte protease inhibitor after spinal cord injury.ZIP4 confers resistance to zinc deficiency-induced apoptosis in pancreatic cancer.Fibroblast growth factor receptors 1 and 2 in keratinocytes control the epidermal barrier and cutaneous homeostasis.CFIm25 links alternative polyadenylation to glioblastoma tumour suppression.Profilin-1 suppresses tumorigenicity in pancreatic cancer through regulation of the SIRT3-HIF1α axis.Secretory leukocyte protease inhibitor plays an important role in the regulation of allergic asthma in mice.Overcoming drug resistance in pancreatic cancer.Genomic profiling guides the choice of molecular targeted therapy of pancreatic cancer.Imaging-guided curative surgical resection of pancreatic cancer in a xenograft mouse model.ZIP4 silencing improves bone loss in pancreatic cancerStudy human pancreatic cancer in mice: how close are they?FGF receptors 1 and 2 are key regulators of keratinocyte migration in vitro and in wounded skinVertebrate animal models of glioma: understanding the mechanisms and developing new therapies.The role of chronic inflammation in cutaneous fibrosis: fibroblast growth factor receptor deficiency in keratinocytes as an example.Role of runt-related transcription factor 2 in signal network of tumors as an inter-mediator.MicroRNA-34b inhibits pancreatic cancer metastasis through repressing Smad3.Induction of macrophage-derived SLPI by Mycobacterium tuberculosis depends on TLR2 but not MyD88.ZIP4 Promotes Pancreatic Cancer Progression by Repressing ZO-1 and claudin-1 through a ZEB1-Dependent Transcriptional Mechanism.STAT3/HOTAIR Signaling Axis Regulates HNSCC Growth in an EZH2-dependent Manner.PIN1 maintains redox balance via the c-Myc/NRF2 axis to counteract Kras-induced mitochondrial respiratory injury in pancreatic cancer cellsA preoperative serum signature of CEA+/CA125+/CA19-9 ≥ 1000 U/mL indicates poor outcome to pancreatectomy for pancreatic cancerZIP4 is a novel diagnostic and prognostic marker in human pancreatic cancer: a systemic comparison between EUS-FNA and surgical specimensLocal Phototherapy Synergizes with Immunoadjuvant for Treatment of Pancreatic Cancer through Induced Immunogenic Tumor VaccineA Novel Oxoglutarate Dehydrogenase-Like Mediated miR-214/TWIST1 Negative Feedback Loop Inhibits Pancreatic Cancer Growth and Metastasis
P50
Q26829873-E162B36A-B1D8-4E42-A5B0-420DC8D0FEE2Q27027711-194E1542-F7E2-4653-9A86-9B76F9EBC6B3Q33570020-9C5841EC-5BE3-4AF0-85B9-E3D469E5C914Q33578613-95F31668-7CA7-480F-BE5E-174A88A183D3Q33751715-FB27CBDA-5FEF-4806-82B9-E56F7663BF43Q34027447-23B5FE66-2A15-4032-BED2-B5CD69F48F07Q34598059-DD45A328-72B5-422E-B77B-1442229FE394Q35014657-FB206BB6-0927-4198-ADF5-2D3F9DBE2650Q35036615-2C211951-45C3-4C4F-92CD-7AFE08127C0EQ35671422-46DBDC2F-B1A4-49C5-8CC5-2F149A66CFC9Q36140019-E52E4411-3D45-4FC0-A340-FE0AA1FE348FQ36413357-B8C1F8AE-B699-4600-A923-E7FC1013A56CQ36511937-2C16F633-56D4-4E66-93BD-69237F1615CAQ36619447-ED25C87F-BF41-4C1A-A610-70C019C634A0Q37058923-4E35600B-1D04-49DE-B62D-9FB45B5199F2Q37955061-87330BC8-78D7-4E0B-8C17-FAA6C3974033Q38366359-709E43BE-B56F-4DE8-8124-9DB434FAF973Q43550594-861295CC-28AA-48BC-8D6D-F76D24E684B2Q46762923-814073FD-9143-4117-BEEE-DE6AF7AC4223Q52609132-795351BA-26A8-4A5E-9564-452936918216Q52655496-C65E0F14-F269-4312-8563-4ADA646B04D9Q57790435-4203238A-7788-4ADD-B981-1614E2F6C4A8Q85662486-A211AD81-31B3-42B4-A153-706E59D2E3ABQ86960850-A3340A54-62E5-4A29-B67A-CBDC7BC056ACQ90697648-5C18ECC0-FCBA-4D07-8461-B8BD39C508CFQ92594588-DCA4AE9C-C134-4458-A8A2-8D3825F8EC52
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Jingxuan Yang
@ast
Jingxuan Yang
@en
Jingxuan Yang
@es
Jingxuan Yang
@nl
type
label
Jingxuan Yang
@ast
Jingxuan Yang
@en
Jingxuan Yang
@es
Jingxuan Yang
@nl
prefLabel
Jingxuan Yang
@ast
Jingxuan Yang
@en
Jingxuan Yang
@es
Jingxuan Yang
@nl
P106
P108
P1153
54418361900
P31
P496
0000-0003-3265-161X